--- title: Hemostemix’s Insider Lead Order of $330,000 Private Placement description: Hemostemix announces a $330,000 lead order for its non-brokered private placement, offering units at $0.11, plus warrants, to raise up to $700,000. --- [Skip to content](https://hemostemix.com/latest-news/hemostemixs-insider-lead-order-of-330000-private-placement-1#main-content) [![LOGO_Primary](https://hemostemix.com/hs-fs/hubfs/LOGO_Primary.png?width=200&height=100&name=LOGO_Primary.png)](https://hemostemix.com) - [Patients](https://hemostemix.com/investigational-treatment-options) - [Physicians](https://hemostemix.com/physicians) - ACP-01 Show submenu for ACP-01 - [ACP-01](https://hemostemix.com/acp-autologous-stem-cell-therapy) - [Clinical Research](https://hemostemix.com/clinical-research) - Conditions Show submenu for Conditions - [Peripheral Arterial Disease PAD](https://hemostemix.com/peripheral-arterial-disease-pad-and-peripheral-ischemia) - [Chronic Limb Threatening Ischemia CLTI](https://hemostemix.com/chronic-limb-threatening-ischemia) - [Cardiovascular Ischemia/Angina](https://hemostemix.com/cardiovascular-ischemia-angina) - [Vascular Dementia](https://hemostemix.com/vascular-dementia) - [Wound Care](https://hemostemix.com/wound-care) - Blog Show submenu for Blog - [Hemostemix Health Hub](https://hemostemix.com/health-hub-blog) - [Hemostemix Video Library](https://hemostemix.com/videolibrary) - [About](https://hemostemix.com/about) Open main navigation Close main navigation - [Patients](https://hemostemix.com/investigational-treatment-options) - [Physicians](https://hemostemix.com/physicians) - ACP-01 Show submenu for ACP-01 - [ACP-01](https://hemostemix.com/acp-autologous-stem-cell-therapy) - [Clinical Research](https://hemostemix.com/clinical-research) - Conditions Show submenu for Conditions - [Peripheral Arterial Disease PAD](https://hemostemix.com/peripheral-arterial-disease-pad-and-peripheral-ischemia) - [Chronic Limb Threatening Ischemia CLTI](https://hemostemix.com/chronic-limb-threatening-ischemia) - [Cardiovascular Ischemia/Angina](https://hemostemix.com/cardiovascular-ischemia-angina) - [Vascular Dementia](https://hemostemix.com/vascular-dementia) - [Wound Care](https://hemostemix.com/wound-care) - Blog Show submenu for Blog - [Hemostemix Health Hub](https://hemostemix.com/health-hub-blog) - [Hemostemix Video Library](https://hemostemix.com/videolibrary) - [About](https://hemostemix.com/about) - [Contact us](https://hemostemix.com/contact-us) [Contact us](https://hemostemix.com/contact-us) [All posts](https://hemostemix.com/latest-news/all) March 19, 2026 # Hemostemix’s Insider Lead Order of $330,000 Private Placement ![Picture of Hemostemix](https://hemostemix.com/hs-fs/hubfs/Old%20Site%20Files/sublogo.png?width=50&name=sublogo.png) By  Hemostemix  ·  1 minute read Calgary, Alberta, October 7, 2025 - Hemostemix (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("**Hemostemix**" or the "**Company**") is pleased to announce a lead order of $330,000 for a non brokered private placement of up to $700,000. Purchasers may subscribe for Units at $0.11. Each Unit consists of one Common Share and one Warrant. Each Warrant may be exercised by the holder to acquire one Common Share at $0.15 for a period of two years from the Closing Date, subject to the following accelerator: If, on any 10 consecutive trading days occurring after four months and one day has elapsed following the Closing Date, the closing sales price of the Common Shares (or the closing bid, if no sales were reported on a trading day) as quoted on the Exchange is greater than a weighted average price of **$0.185** per common share, the Corporation may provide notice in writing to the holders of the warrants by issuance of a press release that the expiry date of the warrants is accelerated to the date that is 30 days following such press release.   A Director of the Company is participating in the Offering, which constitutes a "related party transaction" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") and the policies of the TSXV. The Company is relying upon the exemptions from the formal valuation and minority shareholder approval requirements pursuant to sections 5.5(b) and 5.7(1)(a), respectively, of MI 61-101 on the basis that the Company is not listed on a specified stock exchange and, at the time the Offering was agreed to, neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the transaction insofar as it involves an interested party (within the meaning of MI 61-101) in the Offering, exceeds 25% of the Company's market capitalization calculated in accordance with MI 61-101. Share [facebook-f icon](http://www.facebook.com/share.php?u=https://hemostemix.com/latest-news/hemostemixs-insider-lead-order-of-330000-private-placement-1) [linkedin-in icon](http://www.linkedin.com/shareArticle?mini=true&url=https://hemostemix.com/latest-news/hemostemixs-insider-lead-order-of-330000-private-placement-1) [twitter icon](https://twitter.com/intent/tweet?url=https://hemostemix.com/latest-news/hemostemixs-insider-lead-order-of-330000-private-placement-1) [pinterest-p icon](http://pinterest.com/pin/create/link/?url=https://hemostemix.com/latest-news/hemostemixs-insider-lead-order-of-330000-private-placement-1) [envelope icon](mailto:?body=https://hemostemix.com/latest-news/hemostemixs-insider-lead-order-of-330000-private-placement-1) [![LOGO_Primary](https://hemostemix.com/hs-fs/hubfs/LOGO_Primary.png?width=218&height=109&name=LOGO_Primary.png "LOGO_Primary")](https://hemostemix.com/) [Contact Us](https://hemostemix.com/contact-us) [facebook-f icon](https://www.facebook.com) [linkedin-in icon](https://www.linkedin.com) [twitter icon](https://www.x.com) [instagram icon](https://www.instagram.com) - [Publications](https://hemostemix.com/scientific-publications) - [Product Pipeline](https://hemostemix.com/product-candidates) - [News](https://hemostemix.com/latest-news) - [Investors](https://hemostemix.com/clinical-research) - [Team](https://hemostemix.com/videolibrary) - +1 905-580-4170 - tsmeenk@hemostemix.com - 707 7th Ave SW #1150, Calgary, AB T2P 3H6, Canada Copyright © 2025 Hemostemix, Inc. ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Hemostemix", "url" : "https://hemostemix.com/latest-news/author/admin" }, "dateModified" : "2026-04-27T17:39:25.116Z", "datePublished" : "2026-03-19T05:04:04.000Z", "headline" : "Hemostemix’s Insider Lead Order of $330,000 Private Placement", "mainEntityOfPage" : { "@id" : "https://hemostemix.com/latest-news/hemostemixs-insider-lead-order-of-330000-private-placement-1", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://hemostemix.com/hubfs/Hemostemix%20Logos%20(400%20x%20100%20px).png" }, "name" : "Hemostemix" } } ``` ```json { "@context" : "http://schema.org", "@type" : "Article", "author" : { "@type" : "Person", "name" : [ "Hemostemix" ] }, "datePublished" : "2026-03-19T05:04:04+0000", "description" : "Hemostemix announces a $330,000 lead order for its non-brokered private placement, offering units at $0.11, plus warrants, to raise up to $700,000.", "headline" : "Hemostemix’s Insider Lead Order of $330,000 Private Placement", "image" : "", "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://243653617.fs1.hubspotusercontent-na2.net/hubfs/243653617/Hemostemix%20Logos%20(400%20x%20100%20px).png" }, "name" : "Hemostemix" }, "url" : "https://hemostemix.com/latest-news/hemostemixs-insider-lead-order-of-330000-private-placement-1" } ```